Current NCCN guidelines only recommend screening for BM in breast cancer patients with suspicious neurological symptoms in advanced-stage (IV) or recurrent disease.9 Predictors of BM in breast cancer patients include: Younger age, presence of visceral metastases, number of metastasis sites, and HER2+ and TN molecular subtypes.12,61 However, the rates of BM in these subgroups are not high enough to justify screening according to the current consensus.62 Nonetheless, these data are generated from smaller studies with conflicting recommendations. Here, ERBB2 is linked to breast carcinoma.